Shares of Aptinyx Inc (NASDAQ:APTX) have been assigned an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.56.
Several research analysts have recently weighed in on the stock. Svb Leerink assumed coverage on shares of Aptinyx in a report on Thursday, June 20th. They issued an “outperform” rating and a $12.00 price target on the stock. BMO Capital Markets upped their price target on shares of Alimentation Couche-Tard from C$79.00 to C$84.00 and gave the stock an “outperform” rating in a report on Friday, March 22nd. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Tuesday. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a research note on Tuesday, April 30th.
Shares of Aptinyx stock traded down $0.05 during trading on Monday, hitting $3.72. The stock had a trading volume of 108,585 shares, compared to its average volume of 317,753. Aptinyx has a 12 month low of $2.88 and a 12 month high of $32.25. The company’s 50-day moving average price is $3.40.
In other news, Director Henry O. Gosebruch bought 100,000 shares of Aptinyx stock in a transaction that occurred on Wednesday, May 8th. The shares were acquired at an average price of $3.86 per share, with a total value of $386,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.47% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can purchased a new stake in Aptinyx during the fourth quarter valued at about $40,000. Gabelli Funds LLC purchased a new stake in shares of Aptinyx during the first quarter worth about $44,000. Alambic Investment Management L.P. purchased a new stake in shares of Aptinyx during the first quarter worth about $87,000. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Aptinyx by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after purchasing an additional 5,652 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Aptinyx by 87.1% during the fourth quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after purchasing an additional 4,340 shares during the period. 58.37% of the stock is currently owned by institutional investors and hedge funds.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Story: Hedge Funds
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.